Small molecule degraders of the hepatitis C virus protease reduce susceptibility to resistance mutations

Targeted protein degradation is a promising drug development paradigm. Here we leverage this strategy to develop a new class of small molecule antivirals that induce proteasomal degradation of viral proteins. Telaprevir, a reversible-covalent inhibitor that binds to the hepatitis C virus (HCV) prote...

Descripción completa

Detalles Bibliográficos
Autores principales: de Wispelaere, Mélissanne, Du, Guangyan, Donovan, Katherine A., Zhang, Tinghu, Eleuteri, Nicholas A., Yuan, Jingting C., Kalabathula, Joann, Nowak, Radosław P., Fischer, Eric S., Gray, Nathanael S., Yang, Priscilla L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6672008/
https://www.ncbi.nlm.nih.gov/pubmed/31371704
http://dx.doi.org/10.1038/s41467-019-11429-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6672008/
https://www.ncbi.nlm.nih.gov/pubmed/31371704
http://dx.doi.org/10.1038/s41467-019-11429-w

Ejemplares similares